Vaccines
9 September 2024
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B23 September 2024
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate2 September 2024
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.27 August 2024
Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development27 August 2024
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-80123 August 2024
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants23 August 2024
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine22 August 2024
BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases18 August 2024
Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders14 August 2024
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine6 August 2024
Entos Pharmaceuticals Announces First Participant Dosed in Clinical Trial for COVID-19 Vaccine BoosterNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports